Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:51 AM
Ignite Modification Date:
2025-12-25 @ 2:51 AM
NCT ID:
NCT01793233
Eligibility Criteria:
Inclusion Criteria:
* Patients must have had first menses \>= 6 months prior to enrollment
* Patients must be newly diagnosed with lymphoma; this includes but is not limited to Hodgkin lymphoma, Burkitts lymphoma, diffuse large B cell lymphoma, and anaplastic large cell lymphoma
* Planned cancer treatment must include an alkylating agent: i.e. procarbazine, cyclophosphamide, ifosphamide; planned cancer treatment must be less than one year
* Patients with any performance status are eligible for enrollment
* Patients may take hormone medications excluding gonadotropin-releasing hormone (GnRH) analogues
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
* Patients who have previously received chemotherapy other than steroids and intrathecal chemotherapy are not eligible
* Patients who have a secondary malignancy are not eligible
* Patients with known history of ovarian disease: e.g. Turner syndrome or polycystic ovarian syndrome are not eligible
* Patients in whom planned therapy includes: removal or uterus or ovary(ies), pelvic irradiation, cranial irradiation or hematopoietic stem cell transplantation are not eligible
* Patients who previously have had their uterus or ovary(ies) removed are not eligible
* Patients who have received gonadotropin release hormone agonist or antagonist (e.g. Lupron) prior to study entry are not eligible
* Patients who are pregnant or breast feeding are not eligible
* Patients who have undergone or are planning to undergo ovarian tissue, oocyte or embryo cryopreservation prior to treatment are not eligible
Healthy Volunteers:
False
Sex:
FEMALE
Maximum Age:
29 Years
Study:
NCT01793233
Study Brief:
Protocol Section:
NCT01793233